Why You, Me, and Nature Won at the Supreme Court Today

The law, lawyers, and the court.
June 13 2013 2:51 PM

Patently Unfair

The Supreme Court won’t let the biotech industry own nature—which is good for you and me.

Lab technicians for Myriad Genetics of Salt Lake City, Utah work on DNA samples from the New York State Police, 20 September, 2001.
Lab technicians for Myriad Genetics work on DNA samples in 2001. The company discovered two mutations of the genes BRCA1 and BRCA2 that are associated with a high risk of breast and ovarian cancer, and came up with a test for them.

Photo by George Frey/AFP/Getty Images

I’m trying to remember if I have ever read a Supreme Court opinion by Justice Clarence Thomas with the pleasure I read the one he wrote this morning. For a unanimous court, Thomas did the wise and sensible thing and said no to gene patenting, when the DNA comes straight from nature. Companies can still patent synthetic DNA, because that requires alteration of the gene. Fine. Synthetic gene patents reward scientists for invention. And Thomas is also careful to limit the scope of the ruling so it’s clear that the court isn’t discouraging scientists from coming up with new methods for manipulating genes, altering them, or applying knowledge to them in new ways. That should calm the fears of the biotech industry—their sky is not falling.

But as Thomas explains clearly, the crux of today’s decision rejects the broad claims of Myriad Genetics. (Scalia wouldn’t join the part of the opinion explaining the molecular biology that’s key to this case, but to my inexpert eyes, Thomas’ description looked pretty good.) Hallelujah, because Myriad has been bad for women’s health. The company discovered two mutations of the genes BRCA1 and BRCA2 that are associated with a high risk of breast and ovarian cancer, and came up with a test for them. The bad part was that then Myriad tried to enforce a monopoly on that test by suing everyone else performing tests, based on its broad patents of the genes themselves.

Advertisement

Myriad charged thousands of dollars for its own tests. The company told me most women are covered by insurance, and they have done 5,000 free tests to low-income women without insurance. But that is just 0.4 percent of total cases, according to Duke University researcher Robert Cook-Deegan. When I asked readers about the cost of Myriad’s test, one wrote to me that her insurance wouldn’t cover it, and she couldn’t afford the cost of up to $4,000. “It is a horrifying feeling to be told you have a deadly disease and yet, a helpful and informative test will not be covered by your insurance company,” she writes. “I had to make a major health decision solely on financial reasons. Not a good feeling.” Another reader wrote of his epic saga trying to get testing for his wife before she died of breast cancer in 2009. “On the patient level, Myriad has monopoly pricing, and they refuse to license it to any other lab,” he said. “Besides the outrageous price, it is an insurance nightmare for patients.” All of this has enraged women’s health groups. (One major exception, as Peggy Orenstein points out, is the Komen Foundation, which gets money from Myriad, she says.)

Now Myriad will have to let other companies test for BRCA1 and BRCA2. The company’s doom and gloom prediction is that this will hurt women and science in the end by discouraging invention. Bah. I think the lesson is to watch out before enforcing a patent so aggressively that you infuriate fellow scientists and the people your product is intended to help. Myriad’s 20-year patents of BRCA1 and BRCA2 have almost expired, but its defeat will live on for other patent hungry firms. And there’s also this: The whole idea of patenting a gene—a piece of all of us, me and you—just doesn’t feel right. You can find something “important and useful” in nature, as Thomas puts it, without having the right to own it. The Supreme Court got it right today.



Emily Bazelon was a Slate senior editor from 2005 to 2014. She is the author of Sticks and Stones.

TODAY IN SLATE

Foreigners

More Than Scottish Pride

Scotland’s referendum isn’t about nationalism. It’s about a system that failed, and a new generation looking to take a chance on itself. 

IOS 8 Comes Out Today. Do Not Put It on Your iPhone 4S.

Why Greenland’s “Dark Snow” Should Worry You

Three Talented Actresses in Three Terrible New Shows

The Human Need to Find Connections in Everything

It’s the source of creativity and delusions. It can harm us more than it helps us.

Jurisprudence

Happy Constitution Day!

Too bad it’s almost certainly unconstitutional.

The Ungodly Horror of Having a Bug Crawl Into Your Ear and Scratch Away at Your Eardrum

My Father Was James Brown. I Watched Him Beat My Mother. Then I Married Someone Like Him.

  News & Politics
Weigel
Sept. 17 2014 2:57 PM ISIS Helps Snuff Out Conservative Opposition to Government Funding Bill
  Business
Business Insider
Sept. 17 2014 1:36 PM Nate Silver Versus Princeton Professor: Who Has the Right Models?
  Life
Outward
Sept. 17 2014 1:59 PM Ask a Homo: Secret Ally Codes 
  Double X
The XX Factor
Sept. 17 2014 1:26 PM Hey CBS, Rihanna Is Exactly Who I Want to See on My TV Before NFL Games
  Slate Plus
Slate Fare
Sept. 17 2014 9:37 AM Is Slate Too Liberal?  A members-only open thread.
  Arts
Brow Beat
Sept. 17 2014 1:01 PM A Rare, Very Unusual Interview With Michael Jackson, Animated
  Technology
Future Tense
Sept. 17 2014 12:35 PM IOS 8 Comes Out Today. Do Not Put It on Your iPhone 4S.
  Health & Science
Bad Astronomy
Sept. 17 2014 11:18 AM A Bridge Across the Sky
  Sports
Sports Nut
Sept. 15 2014 9:05 PM Giving Up on Goodell How the NFL lost the trust of its most loyal reporters.